213 filings
8-K
ARQL
Arqule Inc
16 Jan 20
Termination of a Material Definitive Agreement
8:49am
8-K
ARQL
Arqule Inc
17 Dec 19
Entry into a Material Definitive Agreement
11:13am
8-K
ARQL
Arqule Inc
9 Dec 19
Form of Support Agreement
7:31am
8-K
ARQL
Arqule Inc
20 Nov 19
Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
4:05pm
8-K
ARQL
Arqule Inc
30 Oct 19
ArQule Reports Third Quarter 2019 Financial Results
7:30am
8-K
u8a1tc
7 Aug 19
ArQule Reports Second Quarter 2019 Financial Results
7:30am
8-K
yehsby7
25 Jun 19
ArQule Announces Commencement of Proposed Public Offering of Common Stock
5:28pm
8-K
8y5zty
14 May 19
Departure of Directors or Certain Officers
4:30pm
8-K
4vso789dki8f46o6mdc
1 May 19
ArQule Reports First Quarter 2019 Financial Results
7:30am
8-K
b0f9q2syrmw 0npu
15 Apr 19
Departure of Directors or Certain Officers
4:26pm
8-K
ktprmu0xx9gfpk
15 Mar 19
ArQule Announces Management Team Changes
8:00am
8-K
pstm3jfsgaig 30
7 Mar 19
ArQule Reports Fourth Quarter and Full Year 2018 Financial Results
7:30am
8-K
wb1vs37 c9qs
31 Oct 18
ArQule Reports Third Quarter 2018 Financial Results
7:30am
8-K
n8yb9n72gp ho5dc
1 Aug 18
ArQule Reports Second Quarter 2018 Financial Results
7:30am
8-K
d27sv7 bupthm3ul
13 Jul 18
ArQule Announces Commencement of Proposed Public Offering of Common Stock
5:06pm
8-K
yz0uwf
10 May 18
Report of Matters Voted Upon by Stockholders
4:30pm
8-K
mn848m5q
7 May 18
Arqule Reports First Quarter 2018 Financial Results
7:30am
8-K
b0to9j
17 Apr 18
ArQule and Basilea Enter into Exclusive License Agreement for Derazantinib in the US, EU, Japan and Rest of World excluding Greater China
12:00am
8-K
s1bd93cbu19ftfz4
5 Mar 18
ArQule Reports Fourth Quarter and Full Year 2017 Financial Results
12:00am
8-K
10f0gnyvc4t6n
22 Feb 18
Entry into a Material Definitive Agreement
12:00am